Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte precursor cell | 15 studies | 48% ± 19% | |
astrocyte | 14 studies | 32% ± 15% | |
glutamatergic neuron | 12 studies | 69% ± 20% | |
GABAergic neuron | 11 studies | 63% ± 22% | |
oligodendrocyte | 8 studies | 29% ± 13% | |
interneuron | 7 studies | 68% ± 20% | |
retinal cone cell | 7 studies | 33% ± 11% | |
neuron | 6 studies | 50% ± 16% | |
amacrine cell | 6 studies | 35% ± 13% | |
endothelial cell | 5 studies | 40% ± 21% | |
epithelial cell | 4 studies | 37% ± 12% | |
granule cell | 4 studies | 31% ± 24% | |
pericyte | 4 studies | 30% ± 20% | |
retinal ganglion cell | 4 studies | 39% ± 15% | |
retinal bipolar neuron | 4 studies | 25% ± 3% | |
retinal pigment epithelial cell | 4 studies | 39% ± 21% | |
retinal rod cell | 4 studies | 32% ± 23% | |
fibroblast | 4 studies | 18% ± 3% | |
GABAergic interneuron | 3 studies | 68% ± 6% | |
GABAergic amacrine cell | 3 studies | 55% ± 12% | |
OFF-bipolar cell | 3 studies | 30% ± 9% | |
ON-bipolar cell | 3 studies | 38% ± 12% | |
glycinergic amacrine cell | 3 studies | 44% ± 8% | |
ependymal cell | 3 studies | 35% ± 13% | |
smooth muscle cell | 3 studies | 22% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 99% | 2121.53 | 2628 / 2642 | 98% | 9.53 | 690 / 705 |
thymus | 99% | 718.00 | 646 / 653 | 83% | 3.52 | 500 / 605 |
adrenal gland | 96% | 468.68 | 248 / 258 | 84% | 6.82 | 194 / 230 |
ovary | 99% | 860.38 | 179 / 180 | 68% | 1.82 | 293 / 430 |
pancreas | 71% | 195.74 | 234 / 328 | 61% | 1.57 | 108 / 178 |
prostate | 92% | 416.47 | 226 / 245 | 40% | 0.75 | 199 / 502 |
kidney | 72% | 251.92 | 64 / 89 | 58% | 1.31 | 525 / 901 |
uterus | 99% | 743.44 | 169 / 170 | 28% | 1.06 | 127 / 459 |
breast | 83% | 386.76 | 382 / 459 | 30% | 0.66 | 339 / 1118 |
esophagus | 74% | 253.03 | 1072 / 1445 | 36% | 0.93 | 65 / 183 |
bladder | 90% | 332.14 | 19 / 21 | 14% | 0.30 | 72 / 504 |
intestine | 76% | 328.23 | 732 / 966 | 12% | 0.27 | 63 / 527 |
heart | 75% | 250.21 | 647 / 861 | 0% | 0 | 0 / 0 |
adipose | 75% | 369.28 | 904 / 1204 | 0% | 0 | 0 / 0 |
spleen | 74% | 265.32 | 179 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 72% | 286.46 | 961 / 1335 | 0% | 0 | 0 / 0 |
skin | 58% | 184.04 | 1057 / 1809 | 12% | 0.42 | 57 / 472 |
stomach | 31% | 73.18 | 111 / 359 | 15% | 0.33 | 43 / 286 |
lung | 20% | 43.88 | 116 / 578 | 25% | 0.64 | 290 / 1155 |
liver | 26% | 57.69 | 59 / 226 | 6% | 0.10 | 24 / 406 |
tonsil | 0% | 0 | 0 / 0 | 22% | 0.49 | 10 / 45 |
eye | 0% | 0 | 0 / 0 | 9% | 0.18 | 7 / 80 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.12 | 1 / 29 |
muscle | 2% | 4.91 | 19 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 1% | 2.52 | 10 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006915 | Biological process | apoptotic process |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0043565 | Molecular function | sequence-specific DNA binding |
Gene name | CSRNP3 |
Protein name | Cysteine and serine rich nuclear protein 3 Cysteine/serine-rich nuclear protein 3 (CSRNP-3) (Protein FAM130A2) (TGF-beta-induced apoptosis protein 2) (TAIP-2) |
Synonyms | FAM130A2 TAIP2 |
Description | FUNCTION: Binds to the consensus sequence 5'-AGAGTG-3' and has transcriptional activator activity. Plays a role in apoptosis (By similarity). . |
Accessions | B8ZZD9 ENST00000421875.5 ENST00000651982.1 [Q8WYN3-1] Q8WYN3 E7EN18 ENST00000409664.5 ENST00000409420.1 ENST00000342316.8 [Q8WYN3-1] J3KQ49 ENST00000314499.11 [Q8WYN3-1] |